Latest News

This preview highlights key data to watch out for during the 2026 American Academy of Dermatology (AAD) meeting in Denver, Colorado.

ATTD 2026 reveals AI “digital twins,” next-gen closed-loop pumps, and sensors that boost time-in-range and ease diabetes management.

This Q&A highlights Dr. Alexa B. Kimball's responses to questions on the FDA approval of secukinumab for pediatric patients with hidradenitis suppurativa (HS).

The MiniMed Flex is a discreet, smartphone-controlled insulin pump that is roughly the size of 2 stacked insulin vials.

BrainsWay’s SWIFT protocol reduced treatment visits from ~36 to 6 while maintaining response and remission rates in a randomized multisite trial.

FDA clears once-daily icotrokinra for moderate-to-severe plaque psoriasis in adults and teens.

Following the release of new results from the phase 3 ADorable-1 trial on lebrikizumab in pediatric patients, Amy Paller, MD, speaks in a new Q&A interview.

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies

The FDA has issued its third CRL to topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease.

Allergy experts weigh ruxolitinib, tapinarof, and roflumilast—new nonsteroidal creams that reshape atopic dermatitis care beyond steroids.

Experts unpack biologics, molecular know-how, and patient trust—plus key previews for the upcoming AAD Annual Meeting.

Investigational RNA interference therapy targeting prekallikrein enters accelerated regulatory pathway as phase 2 trial evaluates long-acting prophylaxis for HAE.

The FDA has set a PDUFA date of December 30, 2026.

Data from the ACCESS II trial, ACCESS extension study, and a body composition study provide an early look at efficacy and safety data of a new investigational oral GLP-1.

Phase 3 FIND-CKD shows finerenone slows non-diabetic CKD decline by improving eGFR slope; Bayer prepares FDA filing for expanded use.

Lebrikizumab posts strong Phase 3 gains in infants to teens with atopic dermatitis, supporting FDA label expansion and itch relief.

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new trial data, in this week’s essential news roundup.

This FDA approval of secukinumab (Cosentyx) for hidradenitis suppurativa (HS) represents the fourth pediatric indication for the drug.

In this feature, 3 experts discuss the expansion of telehealth and telemedicine use, including their positive and negative aspects in dermatology today.

New biologics transform severe asthma and COPD, yet prednisone overuse persists—see practical selection tips and outpatient steroid stewardship gaps.

New CKD therapies and a cardiometabolic care model are reshaping kidney disease management.

This March episode of The Medical Sisterhood, in honor of Women's History Month, covers building influence in the dermatology field as a woman physician.